MEMORIAL HOSPITAL AND CANCER AND ACUTE LEUKEMIA GROUP B

纪念医院与癌症和急性白血病 B 组

• 批准号: 6513396
• 负责人: CLIFFORD A HUDIS
• 金额: $ 24.84万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-30 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6513396
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): This is the first application for support of Cancer and Leukemia Group B (CALGB) research activities by Memorial Sloan-Kettering Cancer Center (MSKCC) as a Main Member institution. MSKCC's mission is devoted to clinical and laboratory research related to cancer treatment and biology. Previously an affiliate of the New York Hospital, MSKCC became a Main Member in February 1996. This change from affiliate to Main Member represents our commitment to participate in a broad-based cooperative group in order to participate in national group and intergroup randomized trials and to interdigitate the national agenda into our extensive clinical trials program. Strong research interactions already exist between CALGB and MSKCC. Larry Norton, M.D., Chair, Breast Committee, and Jimmie Holland, M.D. first and only Chair, Psycho-Oncology Committee, both play dominant roles in shaping group and national clinical trials. In addition, Nancy Kemeny, M.D., is a member of the GI Committee and Medical Oncology Chair of CALGB 9481, studying intrahepatic chemotherapy in colorectal cancer patients with hepatic metastases. We plan to augment participation in these areas, and Clifford Hudis, M.D., and Andrew Seidman, M.D., are already actively presenting to the Breast Committee. Alice Kornblith, Ph.D., leads several psycho-oncology efforts, and Russell Porenoy, M.D., and Raymond Wesson, Ph.D., will join palliative care and minority issue efforts. Committee participation has expanded, with 19 MSKCC faculty appointed to 12 committees. Protocol accrual has increased, with 69 credits between 3/1/96 and 5/1/97, and 47 credits since 12/96 alone. Increased clinical trial accrual will result from newly activated CALGB therapeutic and nontherapeutic studies from additional disease and modality committees and, by introducing new drugs and biologics under development at MSKCC, into Group studies. This integration is under way. R.S.K. Chaganti, Ph.D., will participate in Leukemia/Lymphoma Correlative Sciences studies by providing the introduction of comparative genomic hybridization into the study of malignant lymphomas. Accrual from affiliation with McGill University will augment MSKCC activities in CALGB. MSKCC looks forward to participation in CALGB's excellent group science.

描述(改编自申请人的摘要)：这是第一个 癌症和白血病B组(CALGB)研究支持申请 纪念斯隆-凯特琳癌症中心(MSKCC)作为主要活动 会员机构。MSKCC的使命是致力于临床和实验室 与癌症治疗和生物学相关的研究。以前是附属公司 1996年2月，MSKCC成为纽约医院的主要成员。这 从附属公司变更为主要成员代表着我们对 参加一个基础广泛的合作小组，以便参加 国家组和组间随机试验，并将 国家议程纳入我们广泛的临床试验计划。研究力量雄厚 CALGB和MSKCC之间已经存在互动。拉里·诺顿医学博士 乳房委员会主席和吉米·霍兰德，医学博士，第一位也是唯一的主席， 心理肿瘤委员会，两者都在塑造团体和 国家临床试验。此外，医学博士南希·凯梅尼也是 CALGB 9481的GI委员会和医学肿瘤学主席，研究 肝内化疗在结直肠癌肝内化疗中的应用 转移瘤。我们计划扩大在这些领域的参与，Clifford 医学博士哈迪斯和医学博士安德鲁·塞德曼已经在积极向 乳房委员会。爱丽丝·科恩布利斯博士领导着几个心理肿瘤学 努力，医学博士拉塞尔·波雷诺伊和博士雷蒙德·韦森将加入 姑息治疗和少数群体问题的努力。委员会的参与有 扩大，有19名MSKCC教职员工被任命为12个委员会的成员。协议 应计项目有所增加，96年3月1日至97年5月1日之间有69个学分，47个学分 仅自1996年12月以来的学分。临床试验收益将增加 来自新启动的CALGB治疗和非治疗研究 增加疾病和模式委员会，并通过引入新药和 MSKCC正在开发的生物制品，进入小组研究。这种整合 正在进行中。R.S.K.Chaganti博士将参与白血病/淋巴瘤 通过提供比较研究的介绍来进行相关科学研究 基因组杂交在恶性淋巴瘤研究中的应用。应计项目来自 与麦吉尔大学的合作将加强MSKCC在CALGB的活动。 MSKCC期待着参与CALGB优秀的群体科学。